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Abstract
Background:  Rabbit syndrome is a movement disorder t h a t  i s  a s s o c i a t e d  w i t h  l o n g - t e r m
exposure to neuroleptic medications. Of particular interest and importance is the risk of rabbit
syndrome with exposure to the newer atypical antipsychotics. Our recent experience with such a
case brought to light the importance of exploring this risk.
Methods: MEDLINE and PubMed (1972–2006) databases were searched for English language
articles using the keywords rabbit syndrome, tardive dyskinesia, antipsychotic, extrapyramidal
symptoms and side effects. A recent case study is used to expand upon the literature available on
newer antipsychotics and rabbit syndrome.
Results: We reviewed papers that addressed the following aspects of rabbit syndrome 1) the
clinical manifestations 2) prevalence and risk factors, 3) etiopathogenesis 4) older antipsychotics
and rabbit syndrome 5) newer antipsychotics, 6) treatment options. Moreover, we report a case
of RS in a 50 year old white female, diagnosed with bipolar I disorder, that, after the discontinuation
of risperidone, developed involuntary movements of the mouth that were fine, rhythmic and rapid,
along the vertical axis, and without involvement of the tongue. After the re-introduction of
risperidone, the symptoms decreased in a few hours and disappeared after 3 days.
Conclusion: Eleven cases of rabbit syndrome have been documented since the implementation of
newer antipsychotics. Future research is needed to better understand the etiopathogenesis of
rabbit syndrome in psychiatric populations treated with the atypical antipsychotics. Understanding
the differences and similarities of rabbit syndrome and tardive dyskinesia is crucial to the creation
of a successful treatment paradigm.
Background
Rabbit syndrome (RS) is characterized by fine, rapid,
rhythmic movements along the vertical axis of the mouth.
Long-term exposure to the older neuroleptics has clearly
been associated with RS, but little is known regarding the
risk of RS due to the exposure to the newer atypical antip-
sychotics. This syndrome is considered a distinct neu-
roleptic-induced extrapyramidal syndrome. There is
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evidence that RS combines features of both Parkinson's
disease and tardive dyskinesia [1-4].
In the present study we review the current knowledge on
the clinical manifestations, the etiopathogenesis, and the
prevalence of the RS. We also report on a patient who
developed the syndrome after discontinuing an atypical
antipsychotic, comment on the few similar cases that have
been recently published, and review the possible treat-
ment options and the outcome of patients developing this
syndrome.
Methods
MEDLINE and PubMed (1972–2006) databases were
searched for English language articles using the keywords
rabbit syndrome, tardive dyskinesia, antipsychotic,
extrapyramidal symptoms. We also performed a chart
review for the case of RS that occurred in one of our
patients upon discontinuation of an atypical neuroleptic.
Results and discussion
Clinical manifestations
RS is characterized by fine, rapid, rhythmic movements
along the vertical axis of the mouth. These involuntary
movements occur at a frequency of approximately 5 Hz.
The oral movements are often accompanied by a popping
sound that is produced by the rapid smacking on one's
lips. This syndrome is limited exclusively to the territory
of the oral and masticatory muscles and does not involve
the tongue [1]. The pattern of movement contrasts tardive
dyskinesia (TD), another form of oral dyskinesia, in
which the tongue is involved in making slower and less
regular movements.
Similar to TD, the movements of RS increase in situations
of fatigue and anxiety. Stressful situations may also be a
trigger for intensifying the symptoms of RS. RS always
worsens during attention, concentration, and motor per-
formances. In these situations, RS is accompanied by an
increase in muscle tone. Jus et al. [5] found that when
patients were asked to follow a labyrinth pattern with a
pencil, RS symptoms intensified. Different from other
types of oral dyskinesias such as buccolingual and bucco-
linguo-masticatory syndromes, RS cannot be suppressed
voluntarily by the patient [6]. RS can be associated with
drug-induced parkinsonism [7,8] and TD [3,9]. RS symp-
toms are similar to Parkinson's symptoms in their persist-
ence during stage 1 non-REM sleep, whereas a cessation of
symptoms is observed in the same situation with TD.
Prevalence and risk factors
RS is believed to be a rare condition affecting only a small
fraction of the psychiatric population using neuroleptics.
Yassa and Lal [8] carried out the first prevalence study by
focusing on the inpatient population of a psychiatric insti-
tution and reported a 2.3% prevalence rate of RS in a sam-
ple of 266 inpatients receiving older neuroleptics, either
as monotherapy or in combination with anticholinergic
agents. The prevalence rate of RS in patients solely taking
neuroleptics was 4.4%. Another prevalence study [10]
found a rate of 1.5% for RS among neuroleptic-treated
patients in a geriatric mental health clinic. To the best of
our knowledge, no prevalence study has been published
to date on the relationship between RS and atypical antip-
sychotics.
Gender and age are also believed to be related to the
development of RS. This syndrome is found predomi-
nantly in middle-aged and elderly patient populations
[11]; women are also believed to be at higher risk for
developing RS than their male counterparts [7]. Data from
Tables 1 and 2 indicates that most of the cases of RS
reported to-date have involved patients with a diagnosis
of schizophrenia. Previous brain damage has also been
associated with RS [1].
Etiopathogenesis
RS may appear during treatment with neuroleptic medica-
tions or after discontinuation of such medicines. The
mechanisms triggering RS are believed to be similar to
those involved in the pathogenesis of the neuroleptic-
induced Parkinsonian syndrome [7]. In fact, RS may be
due to a hypercholinergic state resulting from the neu-
roleptic blockade of dopaminergic neurons in the extrapy-
ramidal system [12]. This would explain the response of
RS to anticholinergic drugs [3,13].
Nishiyama [14], however, reported a case of RS that was
treated successfully using haloperidol in a woman affected
by multiple system atrophy. In this case, the etiopathoge-
netic mechanism of RS may be similar to TD, possibly sug-
gesting a state of cholinergic hypofunction due to a
denervation-type dopaminergic hypersensitivity in the
basal ganglia [15].
Given that the disease mechanism of RS resembles the
mechanism of parkinsonism and the mechanism of TD, it
may be possible to attribute RS to an imbalance of the
cholinergic and dopaminergic function in the basal gan-
glia. However, the etiopathogenesis of RS, parkinsonism,
and TD, are still unclear.
Interestingly, neuroleptic exposure was found to be unre-
lated to following six documented cases of RS [11,16-
18,20]. Truong [16] described a case of RS observed in a
76-year-old female who had undergone brain surgery 16
years earlier. Kamijo [17] reported a case related to inges-
tion of a massive quantity of phenol in a suicide attempt.
Phenol intoxication may have caused RS by inducing
cholinergic dominance in the central nervous system. RSClinical Practice and Epidemiology in Mental Health 2007, 3:6 http://www.cpementalhealth.com/content/3/1/6
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was also observed in patients treated with imipramine, cit-
alopram, paroxetine and methylphenidate [11,18-20]. It
is possible that these antidepressants, potent inhibitors of
serotonin reuptake, caused RS through a serotonin-medi-
ated inhibition of dopaminergic neurotrasmission in the
basal ganglia in predisposed subjects [21,22].
Older antipsychotic medications and Rabbit Syndrome
Several case studies have been published on the relation-
ship between older antipsychotics and RS (table 1). The
use of high-potency neuroleptics with low anticholinergic
activity, like haloperidol, is common to most of these
cases. In fact, of the 34 cases reported in the literature, 12
were associated with haloperidol, and 8 with piperazinic
phenotiazines (Fluphenazine, Perphenazine, Trifluopera-
zine). These high-potency drugs are known for a relative
high tendency to induce parkinsonism [23]. This evi-
dence, coupled with the fact that some patients who
developed RS reported a previous history of the more
usual parkinsonian side-effects [13], substantiates the
hypothesis that RS and drug-induced parkinsonism may
be mediated by a neuroleptic blockade of the same pool
Table 1: Older Antipsychotics and the Rabbit Syndrome.
Patient Age Gender Diagnosis Duration of previous 
antipsychotic 
treatment
Drug (mg) Parkinsonian 
Syntoms
Tardive 
Dyschinesia
Patient 1 [1] 66 F Schizophrenia Several years Perphenazine (8) No No
Patient 2 [1] 67 F Schizophrenia Several years Trifluoperazine (5)
Benzotropine
Yes Yes
Patient 3 [1] 54 F Schizophrenia Several years Clhorpromazine (50)
Trifluoperazine (5)
Thioridazine (50)
Yes No
Patient 4 [1] 66 M Schizophrenia Several years Trifluoperazine (5)
Methotrimipramine (125)
Benzotropine (2)
No No
Patient 5 [1] 47 M Schizophrenia Several years Thioridazine (100) Yes No
Patient 6 [2] Between 47 and 62 M - Several years - No No
Patient 7 [2] Between 47 and 62 M - Several years - No No
Patient 8 [2] Between 47 and 62 M - Several years - No No
Patient 9 [2] Between 47 and 62 F - Several years - No No
Patient 10 [2] Between 47 and 62 F - Several years - No No
Patient 11 [2] Between 47 and 62 F - Several years - No No
Patient 12 [3] 54 F Schizophrenia 10 years Fluphenazine decanoate (25) No Yes
Patient 13 [25] 62 F Schizophrenia 18 months Mesoridazine (100)
Clorazepate
No No
Patient 14 [25] 68 F Schizophrenia 10 years Thioridazine (25) No Yes
Patient 15 [28] 63 F Schizophrenia Several Fluphenazine decanoate Fluphenazine (20) Yes No
Patient 16 [28] 66 M Bipolar disorder 8 days Haloperidol (260) Yes No
Patient 17 [8] 42 F Schizophrenia 16 months* Haloperidol (90) Yes -
Patient 18 [8] 50 F Schizophrenia 9 months* Haloperidol (10) No -
Patient 19 [8] 57 M Schizophrenia 7 months* Haloperidol (8) Yes -
Patient 20 [8] 67 F Bipolar disorder 8 months* Haloperidol (8) Yes -
Patient 21 [8] 71 F Korsakoff's syndrome 12 months* Haloperidol (8)
Chlorpromazine (150)
Yes -
Patient 22 [8] 77 M Mental retardatio 12 months * Haloperidol (7) Yes -
Patient 23 [12] 52 M Schizophrenia 20 years - No No
Patient 24 [13] 75 M Schizophrenia 30 years Trifluoperazine (15)
Fluphenazine decanoate (37.5)
No Just 
before
No
Patient 25 [7] 63 F Schizophrenia 11 years Haloperidol (8)
Levopromazine (50)
Lithium (600)
Yes No
Patient 26 [7] 63 F Schizophrenia 32 years Propericiazine (50)
Clocapramine (100)
Yes
Patient 27 [7] 44 F Schizophrenia 13 years Haloperidol (5)
Propericiazine (60)
Sulpiride (1200)
Yes No
Patient 28 [7] 48 F Schizophrenia 31 years Haloperidol (5)
Levopromazine (150)
Sulpiride (1200)
Yes No
Patient 29 [7] 58 M Schizophrenia 11 years Bromperidol (20)
Sulpiride (600)
Yes No
Patient 30 [10] 77 F Schizophrenia 15 months Thioridazine (75) No No
Patient 31 [4] 57 F Acute paranoid episode 19 months Haloperidol (30–50) No No
Patient 32 [29] 31 F Schizophrenia 14 years Haloperidol (5) No No
Patient 33 [26] 28 F Schizophrenia 5 years Zuclopentixol (200)
Biperidene (4)
No No
Patient 34 [19] 65 F Major depression 10 years Perphenazine (2)
Amitriptyline (25)
Paroxetine (20)
No No
Patients identified by MEDLINE database search in December 2006.Clinical Practice and Epidemiology in Mental Health 2007, 3:6 http://www.cpementalhealth.com/content/3/1/6
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of dopaminergic neurons in the extrapyramidal system
[3].
Newer antipsychotic medications and the Rabbit 
Syndrome
To our knowledge, there are 10 reported cases of RS
related to newer antypsychotics (table 2). Seven of the ten
reported cases of RS are linked to risperidone. Risperidone
is considered to be the atypical antipsychotic with the
highest incidence of extrapyramidal symptoms [24]. This
high incidence may be caused by the high affinity for the
serotonin type 2 and dopamine type 2 receptors and the
low affinity for cholinergic muscarinic receptors.
The three remaining cases occurred with clozapine, olan-
zapine and aripiprazole, respectively. These atypical
antipsychotics are characterized by a relatively low inci-
dence of extrapyramidal symptoms. It is interesting that,
in the case induced by clozapine, TD preceded RS, which
was developed after treatment for approximately 2 years
with chlorpromazine, haloperidol, and fluphenazine
decanoate, either in monotherapy or in combination.
We have observed a case of RS in a 50 year old white
female. The patient was diagnosed with bipolar I disorder
and was treated with lithium, gabapentin, lorazepam, ris-
peridone, and citalopram. Though the intended treatment
regimen was outpatient, the patient was hospitalized as a
result of a severe depressive episode in which she was una-
ble to care for herself physically. At the time of her admis-
sion, the dose of risperidone was 4 mg/day. Because of a
shuffling gait, moderate drooling, and cog wheeling rigid-
ity, the risperidone was first decreased to 1 mg and, after
1 day, it was completely discontinued. This led to a quick
resolution of the extrapyramidal symptoms. No changes
were made in her psychopharmacological treatment
except for an adjustment of the lithium dose and the addi-
tion of trazodone. About 10 days after the discontinua-
tion of risperidone, the patient developed involuntary
movements of her mouth. The movements were fine,
rhythmic, and rapid, along the vertical axis, and without
lingual involvement. A diagnosis of risperidone with-
drawal emergent RS was made. Risperidone was re-started
at 1.5 mg/day. The symptoms noticeably decreased after a
few hours and completely disappeared after 3 days. No
extrapyramidal symptoms were observed.
Treatment Options
Differently from TD, RS typically responds favorably to
anticholinergic agents such as benztropine, biperiden,
procyclidine and trihexyphenidyl [3]. RS typically disap-
pears a few days after the introduction of an anticholiner-
gic agent [4], but can, on occasion, reappear after stopping
anticholinergic medications [12]. Researchers opted to
implement a new treatment strategy after evidence was
found that some patients with RS treated with an anti-
cholinergic agent later developed TD [3,4,25]. The availa-
bility of the newer atypical antipsychotics has led to the
implementation of additional treatment strategies.
Durst [26] successfully treated RS triggered by the typical
neuroleptic zuclopenthixol by switching the patient from
zuclopenthixol to olanzapine. After the administration of
olanzapine (started at 5 mg/day and titrated up to a target
dose of 10 mg/day), both the RS and the psychotic symp-
toms that the patient was presenting showed significant
improvement. In another report, risperidone-induced RS
not respondent to anticholinergic agents, disappeared
after switching the patient to quetiapine. After 4 weeks of
quetiapine treatment (starting dose of 100 mg/day and
titration up to 700 mg/day) rabbit movements dimin-
ished significantly with further improvements during the
follow-up period [27]. Switching to a new atypical antip-
sychotic with high anti-cholinergic properties, like olan-
zapine or clozapine, may be another possible treatment
strategy for RS [24].
Table 2: Newer Antipsychotics and the Rabbit Syndrome.
Patient Age Gender Diagnosis Drug (mg/day) Duration of 
atypical therapy
Parkinsonian 
symptoms
Tardive 
dyskinasia
Patient 1 [30] 68 F Schizophrenia Risperidone (4) 4 months No No
Patient 2 [31] 27 M Schizophrenia Risperidone (4) 7 months No No
Patient 3 [32] 38 F Schizophrenia Risperidone (decresed from 2 to 1) 8 months No No
Patient 4 [33] 38 M Major depression with psychotic features Risperidone (4) 4 months No No
Patient 5 [34] 48 F Schizophrenia Clozapine (225) 7 months No Yes
Patient 6 [35] 29 F Schizophreniform disorder Aripiprazole (10) 6 weeks Yes No
Patient 7 [36] 56 M Major depression with psychotic features Risperidone (6)
Biperiden (2)
4 months Yes No
Patient 8 [27] 22 M Schizophrenia Risperidone (4)
Biperiden (4)
12 months Yes No
Patient 9 [37] 42 F Bipolar I disorder Risperidone (5) 3 weeks No No
Patient 10 [38] 74 - Bipolar disorder Olanzapine (20) - - -
Patient 11 (our case) 50 F Bipolar I disorder Risperidone (decresed from 4 to 1 and 
discontinued)
3 months Yes NoClinical Practice and Epidemiology in Mental Health 2007, 3:6 http://www.cpementalhealth.com/content/3/1/6
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Conclusion
Since Villeneuve first described RS in 1972 it has been
associated with long-term exposure to the older neurolep-
tics (table 1). In the recent past RS was also observed in
patients treated with the newer antypsychotics. To date,
11 cases, including the one documented in this paper, of
RS have been reported in patients treated with atypical
antipsychotics. Of these 11 cases, seven were related to the
use or discontinuation of risperidone (table 2). The phar-
macodynamics of risperidone may explain its tendency to
induce RS. Although the possibility of RS should always
be considered in patients treated with atypical neurolep-
tics in general, and with risperidone in particular, it is
important to note that there is a low incidence of this syn-
drome.
RS can be successfully treated. RS responds well to treat-
ment with anticholinergic agents, whereas TD would be
worsened by such a treatment regimen. Conversely the
use of dopamine depleters like reserpine, which have
proven effective with TD, may worsen RS. Once again, this
underscores the importance of distinguishing between
these two syndromes. RS can be distinguished from typi-
cal oral dyskinesias because the movements observed in
the latter are slower and less regular, involve the tongue,
can be suppressed voluntarily by the patient, and do not
persist during stage I non-REM sleep.
Abbreviations
RS, rabbit syndrome
TD, Tardive dyskinesia
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